Report cover image

Uterine Fibroids Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146957

Description

Uterine fibroids affect approximately 80% of the global female population. Around 1 in 3 or 4 women in their reproductive age are prone to get affected by the condition. More than 50% of the affected women are asymptomatic. Abnormal uterine bleeding is one of the most common symptoms exhibited in 64% of women with fibroids. The market is witnessing a surge in drug development and treatment alternatives. Major healthcare players and research institutions are investing in drug development, leading to several uterine fibroids drugs in the pipeline.

Report Coverage

The Uterine Fibroids Pipeline Report by Expert Market Research gives comprehensive insights into Uterine Fibroids drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The uterine fibroids report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on Uterine Fibroids.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing uterine fibroids pipeline development activities are covered in this report.

Uterine Fibroids Drug Pipeline Outlook

Uterine fibroids  (also known as leiomyomas or myomas) are small non-cancerous growths in the uterus. There are not many distinctive symptoms for uterine fibroids, however, painful periods with heavy menstrual bleeding, pelvic pain or pressure, pain during intercourse, and trouble in urination may occur in patients affected by the condition. These fibroids may vary in size or number. Fibroids are more common in women in their reproductive age and may shrink as they hit menopause. The presence of fibroids is commonly diagnosed through a routine pelvic exam. Ultrasounds, MRIs, hysterosonography, hysterosalpingography and hysteroscopy can also be used.

Treatment for uterine fibroids involves the administration of medicines, non-invasive procedures like MRI-guided focused ultrasound surgery (FUS), and minimally invasive procedures like uterine artery embolization, laparoscopic or robotic myomectomy. Uterine fibroids drugs are the most common initial treatment for the condition. Gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, selective progesterone receptor modulators (SPRMs), progestins, and anti-fibrinolytic agents are some of the drug classes used to manage the disease and reduce the size of fibroids.

Uterine Fibroids – Drug Pipeline Therapeutic Assessment

This section of the uterine fibroids pipeline report covers the analysis of uterine fibroid drugs based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s uterine fibroids therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Gonadotropin-Releasing Hormone (GnRH) Agonists
  • GnRH Antagonists
  • Selective Progesterone Receptor Modulators (SPRMs)
  • Progestins
  • Combined Oral Contraceptives
  • Anti-fibrinolytic Agents
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Aromatase Inhibitors
By Route of Administration

EMR’s uterine fibroids report insights cover 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Uterine Fibroids – Pipeline Assessment Segmentation, By Phases

The uterine fibroids report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials conducted, with over 80 drugs in the pipeline.

Uterine Fibroids – Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under uterine fibroids pipeline analysis include gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, combined oral contraceptives, selective progesterone receptor modulators (SPRMs), nonsteroidal anti-inflammatory drugs (NSAIDs), progestins, aromatase inhibitors and anti-fibrinolytic agents and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.

Uterine Fibroids Clinical Trials Assessment – Competitive Dynamics

The EMR report for the Uterine Fibroids pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uterine fibroids clinical trials:
  • Repros Therapeutics Inc.
  • Myovant Sciences GmbH
  • Bayer AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Industries, Ltd
  • Others
Uterine Fibroids – Emerging Drugs Profile

Letrozole

This drug is being evaluated for the treatment of uterine fibroid-related symptoms as a part of the PLUM Study, which is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial. It is under Phase 4 of the interventional study.

Proellex

Currently, under phase 2 of a multi-centre, parallel design, randomized study, this uterine fibroids drug candidate is under investigation to determine its safety and efficacy for premenopausal women with symptomatic uterine fibroids. Proellex ® (Telapristone Acetate), is developed by Allergan and is administered vaginally.

Progenta (CDB-4124)

Sponsored by Repros Therapeutics Inc., Progenta, a symptomatic uterine fibroids emerging drug, is currently under early-phase evaluation in women. The trial involves administering 3 doses of Progenta (12.5, 25, 50 mg) against the placebo.

Reasons To Buy This Report

The Uterine Fibroids Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for uterine fibroids. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Uterine Fibroids – Pipeline Assessment Report
  • What is the current landscape of uterine fibroids pipeline drugs?
  • Which companies/institutions are developing uterine fibroids drug candidates?
  • How many phase II drugs are currently present in uterine fibroids pipeline drugs?
  • Which company is leading the uterine fibroids pipeline development activities?
  • What is the current uterine fibroids therapeutic assessment?
  • What are the opportunities and challenges present in the uterine fibroids drug pipeline landscape?
  • What is the efficacy and safety profile of uterine fibroids pipeline drugs?
  • Which companies/institutions are involved in uterine fibroids collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in uterine fibroids?
Related Reports

Global Uterine Fibroid Treatment Devices Market

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Uterine Fibroids
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Uterine Fibroids
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Uterine Fibroids: Epidemiology Snapshot
5.1 Uterine Fibroids Incidence by Key Markets
5.2 Uterine Fibroids– Patients Seeking Treatment in Key Markets
6 Uterine Fibroids: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Uterine Fibroids: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Uterine Fibroids, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Uterine Fibroids Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Uterine Fibroids Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 ExAblate 2000
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Relugolix
10.2.3 Vilaprisan
10.2.4 Other Drug
11 Uterine Fibroids Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Leuprorelin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Telapristone Acetate
11.2.3 Other Drugs
12 Uterine Fibroids Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 PRA-027
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Uterine Fibroids Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Uterine Fibroids, Key Drug Pipeline Companies
14.1 Repros Therapeutics Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Myovant Sciences GmbH
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Bayer AG
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 AbbVie Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Takeda Pharmaceutical Industries, Ltd
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us